GlaxoSmithKline: positive results for HIV two-drug regimen
(CercleFinance.com) - GlaxoSmithKline said on Thursday a two-drug regimen showed positive results in controling HIV in treatment-naïve patients.
GSK's ViiV Healthcare said two phase III studies comparing a two-drug regimen with a three-drug regimen met their primary endpoint for non-inferiority, based on standard measure of HIV control after 48 weeks.
ViiV now plans for regulatory submissions for this two-drug regimen, that combines dolutegravir and lamivudine, later this year.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
GSK's ViiV Healthcare said two phase III studies comparing a two-drug regimen with a three-drug regimen met their primary endpoint for non-inferiority, based on standard measure of HIV control after 48 weeks.
ViiV now plans for regulatory submissions for this two-drug regimen, that combines dolutegravir and lamivudine, later this year.
Copyright (c) 2018 CercleFinance.com. All rights reserved.